Showing results (191-200 of 259) with videos related to
Sort By:
Pageof 26
Lung Cancer (Amsterdam, Netherlands)|February 14, 2026
Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysisHidetoshi Hayashi, Byoung Chul Cho, Yu Jung Kim, et al.Clinical Lung Cancer|November 27, 2025
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trialJames Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, et al.Journal of Cancer Research and Clinical Oncology|February 21, 2019
First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progressionMartin Schuler, Eng-Huat Tan, Kenneth O'Byrne, et al.Lung Cancer (Amsterdam, Netherlands)|November 10, 2019
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancerSai-Hong Ignatius Ou, Shirish M Gadgeel, Fabrice Barlesi, et al.The Lancet. Oncology|May 16, 2022
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 studyByoung Chul Cho, Delvys Rodriguez Abreu, Maen Hussein, et al.Cancer Science|July 5, 2018
Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutationsHaruyasu Murakami, Hiroshi Nokihara, Hidetoshi Hayashi, et al.Journal of Cancer|May 29, 2018
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in TaiwanShu-Yung Lin, Ching-Yao Yang, Bin-Chi Liao, et al.The Lancet. Respiratory Medicine|June 2, 2020
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trialYi-Long Wu, Ying Cheng, Jianying Zhou, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2017
Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung CancerJames Chih-Hsin Yang, Sai-Hong Ignatius Ou, Luigi De Petris, et al.The Lancet. Respiratory Medicine|October 24, 2017
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion studyMyung-Ju Ahn, Dong-Wan Kim, Byoung Chul Cho, et al.Pageof 26